← Back to Search

Alkylating agents

cisplatin for Breast Cancer

Phase 2
Waitlist Available
Led By Simon Powell, MD,PhD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing if a pre-treatment biopsy can tell doctors if a patient's cancer will respond to cisplatin and radiation therapy.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response (RECIST 1.1 vs. PET Response Criteria (PRC) as Measurement Tools for Treatment Response)

Side effects data

From 2010 Phase 2 trial • 13 Patients • NCT02006667
46%
Platelet count decreased
38%
Nausea
23%
Fatigue
23%
Vomiting
23%
Chills
23%
White blood cell decreased
23%
Dyspnea
15%
Urinary tract infection
15%
Creatinine increased
15%
Anemia
15%
Weight loss
15%
Investigations-other
15%
Back pain
15%
Paresthesia
15%
Epistaxis
8%
Peripheral sensory neuropathy
8%
Bronchial infection
8%
Nail infection
8%
Alkaline phosphatase increased
8%
Sinus bradycardia
8%
Eyelid function disorder
8%
Bone pain
8%
Non-cardiac chest pain
8%
General disorders and administration site conditions-other
8%
Infections and infestations-others
8%
Diarrhea
8%
Fever
8%
Upper respiratory infection
8%
Confusion
8%
Tachyarrhythmia
8%
Gastrointestinal hermorrhage
8%
Ileus
8%
General disorders-other
8%
Catheter related infection
8%
Hematuria
8%
Urinary tract obstruction
8%
Pleural effusion
8%
Vertigo
8%
Endocrine disorders-other
8%
Neutrophil count decreased
8%
Arthralgia
8%
Pain in extremity
8%
Neck pain
8%
Generalized muscle weakness
8%
Neoplasms benign, malignant and unspecified-others
8%
Depression
8%
Alopecia
8%
Nail ridging
8%
Surgical and medical procedures-others
8%
Chill
8%
Gastrointestinal hemorrhage
8%
Arthritis
8%
Pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Trastuzumab/Gemcitabine/Cisplatin

Trial Design

1Treatment groups
Experimental Treatment
Group I: Concurrent Cisplatin & Radiation TherapyExperimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
external beam radiation therapy
2013
Completed Phase 2
~440
cisplatin
1997
Completed Phase 3
~3290
Biopsy of Target Tumor
2015
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,933 Previous Clinical Trials
585,573 Total Patients Enrolled
203 Trials studying Breast Cancer
81,137 Patients Enrolled for Breast Cancer
Cedars-Sinai Medical CenterOTHER
499 Previous Clinical Trials
164,808 Total Patients Enrolled
17 Trials studying Breast Cancer
2,124 Patients Enrolled for Breast Cancer
Simon Powell, MD,PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kinds of risks do individuals face when taking cisplatin?

"There is evidence of cisplatin's safety, but limited clinical data confirming its efficacy. Therefore, it was assigned a rating of 2."

Answered by AI

Have other investigations explored the effects of cisplatin?

"In 1997, the City of Hope Comprehensive Cancer Center commenced research with cisplatin. Since then, 935 investigations have been concluded and 689 are actively seeking new participants; many being in Uniondale, New jersey."

Answered by AI

Has enrollment for this investigation begun yet?

"According to the data hosted on clinicaltrials.gov, this trial is actively seeking volunteers with registration beginning April 1st 2015 and most recently amended August 8th 2022."

Answered by AI

To what maladies is cisplatin frequently applied?

"Cisplatin is frequently prescribed to battle advanced ovarian cancer. It has also proven effective in treating refractory testicular cancer and other severe maladies."

Answered by AI

How many participants is the research team recruiting for this experiment?

"Yes, the clinicaltrials.gov database shows that this research project is currently enrolling individuals. This trial was launched on April 1st of 2015 and has been revised as recently as August 8th 2022. 54 participants need to be enrolled in total across 7 different sites."

Answered by AI

How extensively is this research available to participants?

"This trial is being administered in 7 distinct healthcare facilities, including Memorial Sloan Kettering Nassau in Uniondale, Memorial Sloan Kettering at Basking Ridge in Basking Ridge, and Memorial Sloan Kettering Cancer Center @ Suffolk in Commack. The other 4 participating sites are also listed on the relevant page of clinicaltrials.gov"

Answered by AI

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
2015. "Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02422498.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top